Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

G. Kees Hovingh; John J.P. Kastelein; Sander J. H. van Deventer; Patrick Round; J. Ford; Danish Saleheen; Daniel J. Rader; H. Bryan Brewer; Philip J. Barter

doi:10.1016/s0140-6736(15)60158-1

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

著者: G. Kees Hovingh, John J.P. Kastelein, Sander J. H. van Deventer, Patrick Round, J. Ford, Danish Saleheen, Daniel J. Rader, H. Bryan Brewer, Philip J. Barter - The Lancet 2015 被引用: 238

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial | Litlas